# Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .

> **NCT07242300** · PHASE3 · NOT_YET_RECRUITING · sponsor: **JHM BioPharma (Tonghua) Co. , Ltd.** · enrollment: 207 (estimated)

## Conditions studied

- Upper Limb Spasticity (ULS)

## Interventions

- **DRUG:** Recombinant Botulinum Toxin Type A for injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07242300
- **Lead sponsor:** JHM BioPharma (Tonghua) Co. , Ltd.
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2026-12
- **Final completion:** 2028-01
- **Target enrollment:** 207 (ESTIMATED)
- **Last updated:** 2025-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07242300

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07242300, "Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .". Retrieved via AI Analytics 2026-09-11 from https://api.ai-analytics.org/clinical/NCT07242300. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*